Fibrobiologics

FBLG · NASDAQ

$0.9199−$0.0199 (−2.12%)TodayMarket closed · Oct 21, 4:07 AM ET

Prev close $0.9398

Latest news

Press releaseOct 19, 8:30 AM ETPRNewswire
FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
Press releaseOct 14, 8:30 AM ETPRNewswire
FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
Press releaseOct 7, 8:30 AM ETPRNewswire
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
NewsOct 7, 8:15 AM ETVandana Singh
EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
Press releaseSep 29, 8:30 AM ETPRNewswire
FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
Press releaseSep 17, 8:30 AM ETPRNewswire
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
Press releaseSep 3, 8:30 AM ETPRNewswire
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Press releaseSep 1, 8:30 AM ETPRNewswire
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
Press releaseAug 27, 8:30 AM ETPRNewswire
FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Press releaseAug 26, 8:30 AM ETPRNewswire
FibroBiologics Regains Compliance with Nasdaq Trading Rules
Press releaseAug 24, 8:30 AM ETPRNewswire
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Press releaseAug 20, 8:30 AM ETPRNewswire
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
NewsAug 18, 9:48 AM ETVandana Singh
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment
Press releaseAug 18, 8:30 AM ETPRNewswire
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Press releaseAug 11, 8:30 AM ETPRNewswire
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
Press releaseAug 5, 8:30 AM ETPRNewswire
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
Press releaseJul 31, 5:34 PM ETPRNewswire
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
Press releaseJul 9, 8:30 AM ETPRNewswire
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
Press releaseJul 7, 8:30 AM ETPRNewswire
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
Press releaseJun 30, 8:30 AM ETPRNewswire
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Press releaseJun 29, 4:01 PM ETPRNewswire
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Press releaseJun 26, 8:30 AM ETPRNewswire
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
NewsJun 3, 6:46 AM ETMohit Manghnani
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
NewsMay 11, 8:32 AM ET
FibroBiologics Announces Strategic Expansion Of Its Fibroblast-Based Platform To Target Hantavirus
Press releaseMay 11, 8:30 AM ETGlobe Newswire
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
NewsMay 4, 8:16 AM ETVandana Singh
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study
Press releaseApr 30, 5:55 PM ETGlobe Newswire
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
Press releaseApr 10, 8:30 AM ETGlobe Newswire
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
NewsApr 1, 5:27 AM ETAvi Kapoor
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
NewsMar 31, 4:02 PM ETVandana Singh
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy
NewsMar 25, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMar 24, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMar 19, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMar 18, 11:30 AM ETGlobe Newswire
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
Press releaseMar 3, 10:02 AM ETPRNewswire
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
Press releaseFeb 24, 4:30 PM ETGlobe Newswire
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
NewsFeb 5, 4:34 AM ETAvi Kapoor
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Press releaseJan 7, 8:30 AM ETGlobe Newswire
FibroBiologics CEO Issues Letter to Shareholders
Press releaseJan 5, 8:30 AM ETGlobe Newswire
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
NewsDec 19, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsDec 15, 12:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 24, 12:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 19, 4:07 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsNov 12, 4:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsNov 6, 4:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs

FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body

EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics Regains Compliance with Nasdaq Trading Rules

FibroBiologics Appoints Leigh Steinberg to Board of Directors

FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease

FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors

FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial

FibroBiologics Announces Strategic Expansion Of Its Fibroblast-Based Platform To Target Hantavirus

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session